追踪CAR-T革命：1997 - 2020年治疗癌症的CAR-T和TCR-T疗法临床试验分析
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020).
作者信息
Ivica Nikola A, Young Colin M
机构信息
Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, USA.
NEWDIGS Initiative, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
出版信息
Healthcare (Basel). 2021 Aug 19;9(8):1062. doi: 10.3390/healthcare9081062.
Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other types of cancer. In this paper, we look at all available FDA CAR-T/TCR-T clinical trials for the treatment of cancer, and analyze them with respect to different disease tissues, targeted antigens, products, and originator locations. We found that 627 of 1007 registered are currently active and of those 273 (44%) originated in China and 280 (45%) in the US. Our analysis suggests that the rapid increase in the number of clinical trials is driven by the development of different CAR-T products that use a similar therapeutic approach. We coin the term bioparallels to describe such products. Our results suggest that one feature of the CAR-T/TCR-T industry may be a robust response to success and failure of competitor products.
嵌合抗原受体和T细胞受体（CAR-T/TCR-T）细胞免疫疗法在治疗某些难治性B细胞恶性肿瘤方面已取得显著成功，有望为其他类型癌症带来持久的临床反应。在本文中，我们研究了美国食品药品监督管理局（FDA）批准的所有用于治疗癌症的CAR-T/TCR-T临床试验，并针对不同的疾病组织、靶向抗原、产品和发起地点进行了分析。我们发现，1007项注册试验中有627项目前仍在进行，其中273项（44%）起源于中国，280项（45%）起源于美国。我们的分析表明，临床试验数量的快速增长是由采用类似治疗方法的不同CAR-T产品的开发推动的。我们创造了“生物平行物”一词来描述此类产品。我们的结果表明，CAR-T/TCR-T行业的一个特点可能是对竞争产品的成功和失败做出强劲反应。
Zotero 插件